Showing 1311-1320 of 9757 results for "".
An Updated, Holistic Approach to Managing Hyperpigmentation
https://practicaldermatology.com/topics/pigmentary-disorders/an-updated-holistic-approach-to-managing-hyperpigmentation/20102/As an early adopter of Cyspera, Suneel Chilukuri, MD has witnessed the evolution of the topical formulation. Cyspera Intensive System provides a three-step holistic approach to skincare that supports healthier, brighter skin within about four to six weeks.Buyer Beware: CBD Products May Peddle False Hope Amid Corona Fears
https://practicaldermatology.com/series/dermatology-dispatches/buyer-beware-cbd-products-may-peddle-false-hope-amid-corona-fears/19775/Any claims that a medical cannabinoid-based product can kill COVID-19 are “absolutely unsubstantiated,” warns Adam Friedman, MD. There is no evidence that these products contain any antiviral properties, and patients should be advised against believing such claims.ABD Eyes Mohs Certification, Sun's Ilumya Approved, FUE Update
https://practicaldermatology.com/topics/psoriasis/dermwiretv-abd-eyes-mohs-certification-sun-s-ilumya-approved-fue-update/18319/The American Board of Dermatology has notified the American Board of Medical Specialties it wants to offer a subspecialty certificate in Micrographic Dermatologic Surgery. Dermatologists react. Ilumya or tildrakizumab from Sun Pharma is approved for moderate to severe psoriasis. Medicine the MusicalASDS: Dr. Downie on Diversity in Dermatology
https://practicaldermatology.com/conferences/asds-2024-annual-meeting/asds-dr-downie-diversity-dermatology/29154/Jeanine B. Downie, MD, FAAD, discusses survey data on different ethnic groups’ cosmetic preferences and the importance of diversity in dermatology at the 2024 American Society for Dermatologic Surgery Annual Meeting.DermWire TV: Positive Data on UCB's Bimekizumab in HS patients; CSF takes Nashville by Storm; Rocatinlimab Performs Well in AD
https://practicaldermatology.com/topics/psoriasis/dermwire-tv-positive-data-on-ucbs-bimekizumab-hs-patients-csf-takes-nashville-by-storm-rocatinlimab-performs-well-in-ad/20159/Bimekizumab performs well in Hidradenitis Suppurativa patients, Cosmetic Surgery Forum takes Nashville by storm, and Rocatinlimab—a novel monoclonal antibody therapy—shows promise in atopic dermatitis are the stories topping the news in this episode of DermWireTV.A Growing Armamentarium for Psoriasis: How to Choose the Right Treatment for Each Patient
https://practicaldermatology.com/topics/psoriasis/a-growing-armamentarium-for-psoriasis-how-to-choose-the-right-treatment-for-each-patient/18214/Erin Boh, MD joins host Joshua Zeichner, MD in this edition of DermTube Journal Club to offer tips for navigating all the new and existing treatment options for patients with moderate to severe psoriasis. With so many effective options on the market, Dr. Boh says it's possible to find the best fit fDupixent, Juvéderm Vollure XC, Bavencio Approvals
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-dupixent-juv-derm-vollure-xc-bavencio-approvals/18698/The FDA has approved Regeneron's injectable Dupixent (dupilumab) to treat adults with moderate-to-severe eczema. It will be marketed by Regeneron and Sanofi Genzyme in the US. Allergan's Juvéderm Vollure XC has received FDA approval based on a pivotal clinical trial in which 59 percent of subjects sPsO Many Options: The Expanded Psoriasis Landscape
https://practicaldermatology.com/topics/psoriasis/pso-many-options-the-expanded-psoriasis-landscape/18749/By Jeffrey Weinberg, MD and Seemal R. Desai, MDWith many new therapies coming out in oral, topical, and biologic forms, there are fewer unmet needs in psoriasis management now than ever before. Dr. Weinberg navigates the therapeutic landscape.Telemedicine and Access, Inappropriate Antibiotics, Industry Growth
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-telemedicine-and-access-inappropriate-antibiotics-industry-growth/18602/New research published online in JAMA Dermatology suggests that teledermatology improves access to care. Experts predict continued growth of telemedicine in dermatology. New estimates suggest that 30% of antibiotic prescriptions may be inappropriate. Dermatologists warn against antibiotic misuse andDWTV Extra: Vitiligo Ingenuity Award
https://practicaldermatology.com/series/dermwire-tv/dwtv-extra-vitiligo-ingenuity-award/37869/Hannah Metheny, a student at the University of Miami Miller School of Medicine, discusses winning an Incyte Ingenuity Award in Vitiligo for the "Barriers and Facilitators to Psychosocial Support as an Integral Aspect of Vitiligo Patient Comprehensive Care" project.